

Glenmark Pharmaceuticals Collaborates with True North's Integrace Health for Its Gynaecology Business in India and Nepal

Torreya advised Glenmark on the transaction

Mumbai, India, January 23, 2020

Glenmark Pharmaceuticals Ltd, a leading global pharmaceutical company based in Mumbai, India, announced a collaboration for its gynaecology business in India and Nepal with Integrace Health Pvt Ltd, a company backed by the private equity firm True North. Integrace Health will be responsible for Glenmark's established gynaecological brands including Dubagest, Mumfer, Fenza and Milical, and also the sales and marketing team of the G&G division.

The transaction enables Glenmark to ensure strategic focus and optimize its resources, thereby leading to higher growth of the business.

Torreya served as a deal advisor to Glenmark Pharmaceuticals on this transaction. This is Torreya's third deal in 2020 and reinforces Torreya's strength and leadership position as an advisor in the commercial asset space. In the past 12 months, Torreya has advised on over 25 transactions in total.

ABOUT GLENMARK PHARMACEUTICALS LTD

For more information about Glenmark, please see: www.glenmarkpharma.com

ABOUT TRUE NORTH

For more information about True North, please see: www.truenorth.co.in



Torreya Contact

NITIN LATH

Managing Director | Mumbai Office

nitin.lath@torreya.com | +91 99-8755-6055 | torreya.com

Torreya is a global advisory firm serving the life sciences industry. Please visit torreya.com for more information. Securities offered in the United States are offered through Torreya Capital LLC, Member FINRA/SIPC. Torreya Partners LLC is a Delaware Limited Liability Company while Torreya Partners (Europe) LLP is a limited liability partnership, registered in England and Wales, registered number OC362930. Registered office: 150 Aldersgate Street, London EC1A 4AB. Torreya Partners (Europe) LLP is authorized and regulated by the Financial Conduct Authority. The information contained in the email and/or its attachments is confidential and/or privileged and is for the sole use of the intended recipient(s). If you are not the intended recipient, please notify the sender immediately by reply and immediately delete this message and all its attachments. Any review, use, reproduction, disclosure or dissemination of the message or any attachment by an unintended recipient is strictly prohibited. Neither this message nor any attachment is intended as or should be construed as an offer, solicitation or recommendation to buy or sell any security or other financial instrument. This communication is for informational purposes only. All investments involve risks including loss of principal invested. Past performance does not guarantee future results or success. Torreya Capital and its representatives do not provide tax or legal advice and each tax and financial situation is unique. Investors should consult their tax and/or legal advisor for advice and information concerning their particular situation.